Localized vs. Systemic Scleroderma: Key Differences in Presentation and Management

Localized Scleroderma (Morphea)

  • Affects skin only (dermis/subcutis)
  • Plaques: hard, thickened, hyper-/hypopigmented
  • May itch or hurt
  • Peak onset: children & young adults
  • Treatment: topical corticosteroids, calcipotriene, phototherapy (UVA1)
  • Prognosis: often self-limited; remission in 3–5 years

Systemic Scleroderma (Systemic Sclerosis, PSS)

  • Affects skin + internal organs + vasculature
  • Skin tightening + Raynaud’s, digital ulcers, ILD, PAH, renal crisis, GI dysmotility
  • Peak onset: women 30–50
  • Treatment: immunosuppressants (methotrexate, mycophenolate), vasodilators, antifibrotics, organ-specific therapy
  • Prognosis: variable; 10-year survival ~70–80% with modern care

Early rheumatology referral is crucial for systemic disease to screen for organ involvement and initiate disease-modifying therapy.

Multiple Sclerosis - Related Articles